- FDA reiterates warning of muscle injury risk when heart drugs combined
- In Brief: PreMD Inc.
- FDA places partial clinical hold on Celgene, MethylGene's cancer drug trials
- FDA reports new cases of pancreatitis seen with Byetta
- Santhera Pharmaceuticals' investigational congenital muscular dystrophy drug receives orphan drug designation
- Eight-week nicotine replacement therapy program improves quit rates compared with a two-week program, study shows
- Certain Medicare beneficiary subgroups failed to fill prescriptions before Part D implementation, new data show
- In Brief: California
- Concomitant asthma, COPD versus either disease alone linked with higher burden, data reveal
- In Brief: Illinois Gov. Rod Blagojevich
Home :: Rheumatology :: Rheumatology Conferences
EULAR 2007 Annual Congress
June 13-16, 2007 Barcelona, Spain- Anti-TNF agents improve signs, symptoms of AS without preventing progression of radiographic damage; many questions remain unanswered, according to panel of experts
- First-line anti-TNF agents yield high rate of long-term response, well tolerated in patients with AS, study demonstrates
- Leflunomide improves symptoms of dactylitis, fatigue, skin disease among patients with PsA, researchers report
- Patients with RA, PsA, AS who have not responded to etanercept, infliximab show response to adalimumab, according to subanalyses
- Biologics represent useful treatment for PsA; other therapies, approaches require more study
ACR 2007 Scientific Meeting
November 6-11, 2007 Boston, MA- Adalimumab, etanercept safe, efficacious in long-term treatment of JRA, researchers report
- Tocilizumab improves function, QOL in patients with RA who respond inadequately to conventional DMARDs, researchers report
- Golimumab improves signs, symptoms, physical function among patients with AS, study data show
- Denosumab, certolizumab show promise as potential treatments in RA
- Infliximab improves spinal mobility in AS, data reveal
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Tocilizumab improves function, QOL in patients with RA who respond inadequately to conventional DMARDs, researchers report
- Golimumab improves signs, symptoms, physical function among patients with AS, study data show
- Targeting the IL-6 cytokine pathway presents exciting opportunities in variety of disease states, experts report
- Abatacept improves disease activity, physical function, QOL in prior, current users of anti-TNF therapy, study data show
- Canadian Rheumatology Association, Spondyloarthritis Research Consortium of Canada publish recommendations for treatment of SpA
- Increase in risk of heart failure slight among younger anti-TNF-treated patients with RA, Crohn's disease
- Disease activity at 3 months closely predicts disease activity at 1 year in patients with RA, study data show
- Etanercept safe, effective in long-term treatment of AS
- Short-term intensive exercise training provides lasting benefits in patients with RA, OA, study data show
All material on this Web site is protected by copyright. Copyright © 1994-2008 by VerusMed, a ConnectivHealth company. This Web site may also contain material copyrighted by third parties.